Jazz Pharmaceuticals PLC
(STU:J7Z)
€
101.45
2.25 (2.27%)
Market Cap: 6.25 Bil
Enterprise Value: 9.77 Bil
PE Ratio: 18.82
PB Ratio: 1.80
GF Score: 74/100 Jazz Pharmaceuticals PLC at RBC Global Healthcare Conference (Virtual) Transcript
May 19, 2020 / 05:20PM GMT
Release Date Price:
€103
Randall S. Stanicky
RBC Capital Markets, Research Division - MD of Global Equity Research & Lead Analyst
Great. Thanks, everybody, for joining us, and good afternoon. I'm Randall Stanicky, pharmaceuticals analyst here at RBC Capital Markets.
And our next company we're pleased to have again at our conference, Jazz Pharmaceuticals. And we have the company's President and Chief Operating Officer, Dan Swisher with us. So Dan, first, thanks for joining us. Really appreciate you guys joining. Let me kick off...
Daniel N. Swisher
Jazz Pharmaceuticals plc - President & COO
Randall, great to be here. I appreciate RBC's support.
Questions & Answers
Randall S. Stanicky
RBC Capital Markets, Research Division - MD of Global Equity Research & Lead Analyst
Great. And let's maybe kick off with a bigger picture question, and I'll jump right in. The Jazz story, I think of it around 3 things: the oxybate franchise, number one; number two, growth and diversification from new products; and then number
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot